East-to-West Oncology Asset Licensing Market

Out-licensing (East-to-West) leads the east-to-west oncology asset licensing market with a 40.1% share in 2026, followed by small molecule oncology drugs at 37.8%. Market activity depends on cross-border licensing partnerships, while asset valuation, clinical evidence quality, intellectual property strength, and clearly defined territorial rights remain the primary determinants of successful transactions.